Pharming Group reports second quarter and first half 2025 financial results and provides business update Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second quarter 2024, reflecting strong growth in patients and prescribersJoenja® (leniolisib) second quarter revenue increased by 15% to US$12.8 million, compared to the second quarter 2024, with a further acceleration in patient uptakeSecond q...
Eramet: Increased focus on operational efficiency following a highly pressured H1 2025 Paris, 30 July 2025, 6:30 p.m. PRESS RELEASE Eramet: Increased focus on operational efficiency following a highly pressured H1 2025 Safety performance remained strong in H1 2025, with a Group TRIFR1 of 0.6 Adjusted EBITDA (excluding SLN)2 at €191m, down 45% vs. H1 2024, primarily from the reduced contribution of PT WBN (-€92m, representing nearly 2/3 of the decline) attributable to: The planned start of new mining production sites at Weda Bay in Indonesia, compounded by constrained operating permit,...
Eramet : priorité à l’efficacité opérationnelle après un 1er semestre 2025 sous forte pression Paris, le 30 juillet 2025, 18h30 COMMUNIQUE DE PRESSE Eramet : priorité à l’efficacité opérationnelle après un 1er semestre 2025 sous forte pression Solide performance en matière de sécurité au S1 2025, avec un TF21 Groupe de 0,6 EBITDA ajusté (hors SLN)2 à 191 M€ en baisse de 45 % par rapport au S1 2024, principalement en raison de la contribution réduite de PT WBN (- 92 M€, soit près de 2/3 de la baisse) s’expliquant par : Le démarrage prévu de nouveaux sites de production minière à Weda B...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.